宫颈癌是全世界女性癌症相关死亡的主要原因，迫切需要有效的治疗解决方案。紫杉醇 (PTX) 是一种天然二萜生物碱化合物，具有抑制有丝分裂并诱导肿瘤细胞程序性凋亡的能力。然而，其毒性和耐药性限制了其对某些宫颈癌患者的疗效。 β-榄香烯（β-ELE）可以通过抑制 ATP 结合盒转运蛋白来逆转多药耐药性，从而增强化疗药物的保留。因此，我们提出使用PTX/β-ELE的联合疗法来提高化疗敏感性。为了增强靶向药物递送，我们开发了 M1-巨噬细胞膜包被的纳米颗粒（M1@PLGA/PTX/β-ELE）用于共同递送 PTX

Cervical cancer is a leading cause of cancer-related mortality in females worldwide, necessitating urgent solutions for effective treatment. Paclitaxel (PTX), a natural diterpene alkaloid compound, has the ability to inhibit mitosis and induce programmed apoptosis in tumor cells. However, its toxicity and drug resistance limit its efficacy in certain cervical cancer patients. β-elemene (β-ELE) can reverse multidrug resistance by inhibiting ATP-binding cassette transporters, thereby enhancing chemotherapy drug retention. Therefore, we propose a combination therapy using PTX/β-ELE to improve chemotherapy sensitivity. To enhance targeted drug delivery, we developed M1-macrophage-membrane-coated nanoparticles (M1@PLGA/PTX/β-ELE) for co-delivery of PTX&β-ELE. Through both in vitro and in vivo cervical cancer models, we demonstrated that M1@PLGA/PTX/β-ELE effectively suppressed tumor progression and polarization of tumor-associated macrophages. Furthermore, H&E staining confirmed the high therapeutic biosafety of M1@PLGA/PTX/β-ELE as there was no significant damage observed in major organs throughout the entire therapeutic process. Overall, this study presents a targeted biomimetic nanoplatform and combinatorial strategy that synergistically enhances chemosensitivity in malignant tumors.© 2024 The Authors.